[
    [
        {
            "time": "2019-09-10",
            "original_text": "The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst Blog",
                    "Allergan",
                    "Merck",
                    "Roche",
                    "J&J",
                    "Bristol-Myers"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-09-10",
            "original_text": "Theravance Announces Positive Early Data on JAK Inhibitor",
            "features": {
                "keywords": [
                    "Theravance",
                    "Positive",
                    "Early Data",
                    "JAK Inhibitor"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-10",
            "original_text": "10 Healthcare Stocks to Buy Despite the Headlines",
            "features": {
                "keywords": [
                    "Healthcare Stocks",
                    "Buy",
                    "Headlines"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 2,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-09-10",
            "original_text": "Health Care Sector Update for 09/10/2019: CANF, MNK, MESO, JNJ, PFE, MRK, ABT, AMGN",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "Update",
                    "CANF",
                    "MNK",
                    "MESO",
                    "JNJ",
                    "PFE",
                    "MRK",
                    "ABT",
                    "AMGN"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-09-10",
            "original_text": "What To Make of Roche's Drugs With $21 Billion In Sales Nearing Patent Expiry?",
            "features": {
                "keywords": [
                    "Roche",
                    "Drugs",
                    "Sales",
                    "Patent Expiry"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-09-10",
            "original_text": "Bristol-Myers Squibb's Revenues: How Does Bristol-Myers Squibb Make Money?",
            "features": {
                "keywords": [
                    "Bristol-Myers Squibb",
                    "Revenues",
                    "Make Money"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]